- Home
- KOD
as 10-17-2025 10:58am EST
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 795.5M | IPO Year: | 2018 |
| Target Price: | $14.33 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.92 - $19.39 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Kodiak Sciences Inc News
KOD Breaking Stock News: Dive into KOD Ticker-Specific Updates for Smart Investing
MT Newswires
11 days ago
Chardan Sets Price Target on Kodiak Sciences at $14, Maintains Neutral Rating
Simply Wall St.
15 days ago
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate
PR Newswire
4 months ago
Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society
GlobeNewswire
4 months ago
Age-Related Vision Dysfunction Market Research 2025-2035 | Kodiak Sciences, Genentech, and AbbVie Drive Innovations Through Advanced, Sustainable Solutions
Zacks
4 months ago
Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?
Simply Wall St.
4 months ago
Talkspace And 2 Other Compelling Penny Stocks To Consider
PR Newswire
5 months ago
Kodiak Sciences to Present at 2025 Jefferies Global Healthcare Conference
Zacks
5 months ago
Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus
Compare KOD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KOD Kodiak Sciences Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.